vTv Therapeutics Inc - Class A (VTVT) gains 2.36% for July 21

Equities Staff  |

vTv Therapeutics Inc - Class A (NASDAQ: VTVT) shares gained 2.36%, or $0.05 per share, to close Wednesday at $2.17. After opening the day at $2.10, shares of vTv fluctuated between $2.27 and $2.06. 1,521,691 shares traded hands a decrease from their 30 day average of 2,091,411. Wednesday's activity brought vTv’s market cap to $127,799,177.

vTv is headquartered in High Point, North Carolina..

About vTv Therapeutics Inc - Class A

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy.

Visit vTv Therapeutics Inc - Class A’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on vTv Therapeutics Inc - Class A and to follow the company’s latest updates, you can visit the company’s profile page here: vTv Therapeutics Inc - Class A’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content